What is Zepbound?
Zepbound is a medication approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition [1]. It is manufactured by Eli Lilly and Company [1].
How does Zepbound work?
Zepbound's active ingredient is tirzepatide [1]. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1]. This dual action helps to reduce food intake and slow gastric emptying, contributing to weight loss [1].
How does Zepbound compare to other weight loss medications?
Tirzepatide, the active ingredient in Zepbound, has also been studied for type 2 diabetes treatment under the brand name Mounjaro [2]. Clinical trials have shown significant weight loss results with tirzepatide, with some studies indicating it leads to greater weight reduction compared to other GLP-1 receptor agonists alone [3].
When does Zepbound's patent expire?
Information regarding the specific patent expiry dates for Zepbound is typically tracked by specialized patent databases [4]. These dates are crucial for understanding when generic versions of the medication might become available.
What are the potential side effects of Zepbound?
Common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite [1]. More serious, but less common, side effects can include pancreatitis, gallbladder problems, kidney injury, severe allergic reactions, and a type of thyroid cancer called medullary thyroid carcinoma [1]. It is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].
Where can I find more information on Zepbound and its patents?
DrugPatentWatch.com provides detailed information on drug patents, including those related to medications like Zepbound [4].
---
Sources:
[1] Eli Lilly and Company. (n.d.). Zepbound™ (tirzepatide) injection. Retrieved from https://www.zepbound.lilly.com/
[2] Mounjaro. (n.d.). Mounjaro (tirzepatide) injection. Retrieved from https://www.mounjaro.com/
[3] Wilding, J. P. H., Andreassen, A. K., Hellberg, M., McGowan, B., & Poudel, V. (2022). Tirzepatide once weekly for the treatment of obesity in adults with overweight or obesity (SURMOUNT-1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 400(10346), 215–227. https://doi.org/10.1016/S0140-6736(22)01430-0
[4] DrugPatentWatch.com. (n.d.). Tirzepatide patents. Retrieved from https://drugpatentwatch.com/drugs/tirzepatide/